Breaking News

AECOM to Buy URS Corp. for $6 Billion, Including Debt
Tweet TWEET

Dendreon Announces Presentation of PROVENGE® (sipuleucel-T) Data at the 2013 ASCO Annual Meeting

  Dendreon Announces Presentation of PROVENGE® (sipuleucel-T) Data at the 2013
  ASCO Annual Meeting

  *Data Evaluate Sequencing of PROVENGE^® (sipuleucel-T) in Treatment of
    Advanced Prostate Cancer and Demonstrate Immune Responses in Patients
    Retreated With PROVENGE^®
  *Preliminary Phase II Data for DN24-02 for High-Risk Urothelial Carcinoma
    Demonstrate Positive Immune Response

2013 ASCO Annual Meeting

Business Wire

SEATTLE -- May 31, 2013

May 31, 2013  – Dendreon Corporation (NASDAQ: DNDN) announced today that four
abstracts featuring PROVENGE^® (sipuleucel-T) data from ongoing Phase II
sequencing studies and the PROCEED registry, and two abstracts highlighting
preliminary Phase II data of DN24-02, an investigational active cellular
immunotherapy in patients with surgically resected HER2+ urothelial cancer,
will be presented at the 49^th Annual Meeting of the American Society of
Clinical Oncology (ASCO) from May 31-June 4, 2013 in Chicago, IL.

Data from an open-label study demonstrate the presence of existing
immunological memory in advanced prostate cancer patients retreated with
PROVENGE several years after initial treatment for androgen dependent prostate
cancer (ADPC) in the Phase III PROTECT study. In addition, the retreatment
appeared to boost product potency compared with prior treatment. Separately,
data from two Phase II studies indicate that PROVENGE can be combined with
androgen deprivation therapy (ADT) or abiraterone acetate plus prednisone.

“These studies help us understand how PROVENGE may be combined or sequenced
with other advanced prostate cancer treatments,” said Mark Frohlich, M.D.,
executive vice president of research and development and chief medical officer
at Dendreon. “We are also pleased with the preliminary data demonstrating that
the antigen-presenting cell activity of DN24-02 for HER2+ urothelial cancer is
similar to that of PROVENGE. The data highlight the promise of our active
cellular immunotherapy platform and furthers Dendreon’s position as a leader
in personalized cancer therapies.”

Studies evaluating PROVENGE and DN24-02 data at ASCO include:

PROVENGE:

  *A Randomized Phase II Study Evaluating the Optimal Sequencing of
    Sipuleucel-T and Androgen Deprivation Therapy (ADT) in
    Biochemically-Recurrent Prostate Cancer (BRPC): Immune Results (Abstract
    5016). Data suggest that combining ADT with sipuleucel-T may augment
    adaptive immunity. PROVENGE is not indicated for the treatment of
    biochemically-recurrent prostate cancer.

Poster discussion session: Genitourinary Cancer, Saturday, June 1, 12:00 PM –
1:00 PM CDT., E Arie Crown Theater Lead Author: Emmanuel Stylianos
Antonarakis, M.D., Sidney Kimmel Comprehensive Cancer Center at John Hopkins
University, Baltimore, MD

  *A Randomized Phase II Trial of Sipuleucel-T with Concurrent or Sequential
    Abiraterone Acetate (AA) Plus Prednisone (P) in Metastatic
    Castrate-Resistant Prostate Cancer (mCRPC) (Abstract 5047). In a Phase II
    clinical study, the data suggest sipuleucel-T can be successfully
    manufactured during concurrent AA plus P with no significant changes in
    peripheral immune responses or alterations in adverse event profiles.

General poster session: Genitourinary Cancer, Monday, June 3, 8:00 AM – 11:45
AM CDT., S Hall A2 Lead Author: Eric J. Small, M.D., Department of Medicine,
University of California San Francisco, San Francisco, CA

  *Impact of Prior Docetaxel on Sipuleucel-T Product Parameters in PROCEED
    Patients (Abstract 5034). In an ongoing, Phase IV registry of patients
    administered sipuleucel-T regardless of prior docetaxel use, the data
    suggest that antigen presenting cell activation in sipuleucel-T is not
    impaired following docetaxel treatment.

General poster session: Genitourinary Cancer, Monday, June 3, 8:00 AM – 11:45
AM CDT., S Hall A2 Lead Author: Celestia S. Higano, M.D., FACP Seattle Cancer
Care Alliance, Seattle, WA

  *Open-Label, Multicenter Study of Sipuleucel-T in Men with Metastatic
    Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with
    Sipuleucel-T: Evaluation of Antigen Presenting Cell (APC) Activation and
    ELISPOT Data (Abstract 5053). In a study designed to evaluate the product
    potency in the retreatment of patients with sipuleucel-T, the data
    indicate the presence of existing immunological memory to sipuleucel-T
    years following initial treatment, and retreatment appeared to boost
    product potency compared with prior treatment. The patients were initially
    treated with sipuleucel-T when they had ADPC, and were retreated after
    they developed mCPRC. PROVENGE is not indicated for the treatment of ADPC
    and the safety and effectiveness of retreatment have not been established.

General poster session: Genitourinary Cancer, Monday, June 3, 8:00 AM – 11:45
AM CDT., S Hall A2 Lead Author: Tomasz M Beer, M.D., Oregon Health & Science
University Knight Cancer Institute, Portland, OR

DN24-02:

  *Preliminary Safety, Product Parameters, and Immune Response Assessments
    From A Phase II Randomized, Open-Label Trial of DN24-02, an Autologous
    Cellular Immunotherapy (ACI), In Patients with Surgically Resected HER2+
    Urothelial Cancer at High Risk for Recurrence (Abstract 4547). In an
    ongoing Phase II study, preliminary data on the adverse events and immune
    response of DN24-02 indicate that antigen presenting cell activity is
    comparable to that of sipuleucel-T and positive immune responses were
    observed.

General poster session: Genitourinary (Nonprostate) Cancer, Monday, June 3,
8:00 AM – 11:45 AM CDT., S Hall A2 Lead Author: Dean F. Bajorin, M.D.,
Memorial Sloan-Kettering Cancer Center, New York, NY

  *Preliminary HER2 Expression Data from NeuACT, the Phase II Randomized,
    Open-Label Trial of DN24-02 in Patients with Surgically Resected HER2+
    Urothelial Cancer (UC) at High Risk for Recurrence (Abstract 4527). In an
    ongoing Phase II study, preliminary data on HER2 expression in urothelial
    cancer suggest a high incidence of HER2 expression (>74%) in urothelial
    cancer primary tumor and lymph node specimens from patients, with higher
    expression observed in lymph node specimens.

Poster discussion session: Genitourinary (Nonprostate) Cancer, Tuesday, June
4, 11:30 AM – 12:30 PM CDT., E354a Lead Author: Michael Press, M.D.,
University of Southern California Norris Comprehensive Cancer Center, Los
Angeles, CA

“Data from the PROTECT study suggest the presence of existing immunological
memory to PROVENGE years following initial treatment and after patients
progressed to mCRPC, and retreatment produced a boost in product potency
compared with prior treatment,” said Tomasz M. Beer, M.D., Grover C. Bagby
Endowed Chair for Prostate Cancer Research, professor of medicine, hematology
& medical oncology and Director of the Prostate Cancer Research Program,
Oregon Health & Science University. “These data suggest that the immune
response from PROVENGE continues well beyond the date of infusion and supports
our understanding of how PROVENGE works over time.”

About PROVENGE

Indication and Important Safety Information

PROVENGE^® (sipuleucel-T) is an autologous cellular immunotherapy indicated
for the treatment of asymptomatic or minimally symptomatic metastatic castrate
resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for
transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in
four randomized clinical trials who underwent at least one leukapheresis. The
most common adverse events (incidence greater-than or equal to 15%) are
chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious
adverse events reported in the PROVENGE group include acute infusion reactions
(occurring within 1 day of infusion) and cerebrovascular events. In controlled
clinical trials, severe (Grade 3) acute infusion reactions were reported in
3.5% of patients in the PROVENGE group. Reactions included chills, fever,
fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache,
hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute
infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing
commitment to patients, Dendreon will conduct a registry of approximately 1500
patients to further evaluate a small potential safety signal of
cerebrovascular events. In four randomized clinical trials of PROVENGE in
prostate cancer patients, cerebrovascular events were observed in 3.5% of
patients in the PROVENGE group compared with 2.6% of patients in the control
group.

For the FDA approved full prescribing information, please visit
http://www.provenge.com.

AboutDendreon

Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon's first
product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug
Administration (FDA) in April 2010. Dendreon is exploring the application of
additional ACI product candidates and small molecules for the potential
treatment of a variety of cancers. The Company is headquartered in Seattle,
Washington and is traded on the NASDAQ Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
http://www.dendreon.com/.

Statements in this press release that are not strictly historical in nature
constitute "forward-looking statements." Such statements include, but are not
limited to, statements regarding the Company's expectations concerning the
settlement of the pending securities litigation against the Company and three
of its current or former officers, the expected benefits of the restructuring,
the timing and elements of the restructuring, the timing and form of related
charges, the expected annual operating expense reduction, expectations and
beliefs regarding Dendreon's financial position, profitability and Dendreon's
ability to break even and achieve improved performance as a result of the
restructuring, expectations regarding reductions of cost of goods sold,
expectations regarding regulatory approval of PROVENGE® in Europe,
expectations regarding the presentation of clinical data, developments
affecting Dendreon's U.S. and global business and prospects and potential
revenue and earnings from product sales, expectations regarding market size
and market opportunity, beliefs regarding the impact of our direct to consumer
advertising, expectations with respect to our sales force execution, and
progress generally on commercialization efforts for PROVENGE. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors which may cause Dendreon's actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. These factors include, but are not limited
to, our ability to complete documentation of the settlement among the parties
to the litigation and with Dendreon's insurers and to obtain court approval of
the settlement, neither of which can be assured; our inability to achieve and
sustain commercial success for PROVENGE; the identification of efficacy,
safety or other issues with PROVENGE; a slower than anticipated adoption by
treating physicians of PROVENGE for the treatment of patients with advanced
prostate cancer due to competing therapies, instability in our sales force,
including the risk that we cannot replace vacant sales positions on a prompt
basis, perceived difficulties in the treatment process, delays in obtaining
reimbursement or for other reasons; any promotional limitations imposed by the
FDA on our ability to commercialize and market PROVENGE; unexpected
difficulties and costs associated with the rapid expansion of our operations
to support the commercial launch of PROVENGE; the impact of competing
therapies on sales of PROVENGE, and other factors discussed in the "Risk
Factors" section of Dendreon's Annual Report on Form 10-K for the year ended
December 31, 2012. All forward-looking statements are qualified in their
entirety by this cautionary statement. Dendreon is providing this information
as of the date of this press release and does not undertake any obligation to
update any forward-looking statements contained in this release as a result of
new information, future events or otherwise.

Contact:

Dendreon Corporation
Corporate Communications
Lindsay Rocco, 862-596-1304
media@dendreon.com
or
Investor Relations
Nicole Soley, 206-455-2220
ir@dendreon.com